Medical devices matter
It was a long time coming, but the new rules regulating medical devices will make a real difference to patient safety, writes Mairead McGuinness.
Mairead McGuinness | Photo credit: Natalie Hill
When the breast implant scandal broke in 2012, there was an outcry from the public and rightly so. How could such a shocking thing happen, that a manufacturer of a medical device (breast implant) would knowingly use a harmful substance in their products, without any concern for the health of women who would receive these implants?
Clearly this was a criminal act and the question we had to ask was, why was this activity not detected in our regulatory system? And how could it continue for so long impacting on thousands of women in many EU member states and beyond our borders?
It was a question that the European Parliament demanded answers to. That pressure for action pushed the European Commission to act and bring forward a new medical devices regulation.
Before the new regulation could be agreed, we needed immediate action and the Commission drew up and implemented an action plan to tighten up controls on the system. The action plan revealed cracks in the system which needed to be addressed, including a tightening up on notified bodies and the need for unannounced inspections.
Work on the regulation has taken a great deal of time. Perhaps it has taken too long, but in the process of negotiating between Commission, Council and Parliament we have managed to come up with concrete steps to improve patient safety - which has to be our core concern.
Trust and confidence of patients in the healthcare system is vital, so any damage done to the reputation of the medical devices sector damaged that essential trust in the system and our work aimed to restore that vital level of trust. Medical devices are wonderful.
The industry that produces them is incredibly innovative and many of us, our family and friends have come in contact with medical devices. For a lot of people these devices, like heart stents or hip replacements, improve the quality of lives. In many cases, these devices save lives. So we were also conscious in our work not to impose overly complex and unnecessary bureaucracy on the industry.
We did not want a regulation which dampened the ability of the industry to continue to innovate and develop devices, but we did want to ensure that devices placed on the market were safe and rigorously assessed.
And so I, and others who worked on this file, were happy that in April of this year the European Parliament adopted the regulation that will enter into force by mid-2020. As one of the MEPs very closely involved, I believe that our work will lead to greater security for patients. The work was incredibly detailed and technical and the proof of the effectiveness of our work over four and a half years will only be known after mid-2020.
I am acutely conscious that we must continue to monitor the work on implementing the regulation. With any file going through the House there are always highs and lows during negotiations - and this file was no different.
However, throughout the intense discussions the overarching goal of achieving and adhering to the highest standards in patient safety guided our work. The efforts of our staff must be recognised as the file involved many long hours of pouring over technical details in order to get things right.
For many of the stakeholders in the sector this will require increased resources right along the supply chain, from the Commission itself, down to the notified bodies and member states' competent authorities. The role of member state authorities is absolutely vital in the correct implementation of the new regulation.
Getting safe products onto the marketplace is important, but so too is post market surveillance and follow up. This means that if a problem arises there must be rapid notification of the incident and rapid recall, if that is what is required.
Sadly with the PIP breast implant scandal, there was poor coordination of reporting of problems, which resulted in the faulty implants being on the market for too long before action was taken.
The introduction of an unique device identification under the new regulation will allow devices to be traced rapidly. Overall the new rules demonstrate how the EU can effectively respond in the interest of its citizens. It may take some time, but even though the regulation will not be fully implemented until 2020, already our work is making a difference as the industry gears up for the new rules.
The attention to detail on this file was crucial in guaranteeing that scandals like the PIP breast implant one, do not occur again. Rules and laws do not stop criminal activity.
However, our new medical devices rules should mean that anyone attempting to take shortcuts will be caught red handed and before their actions damage the health of citizens.
This is of course cold comfort for anyone who was affected by faulty devices in the past. But for the future, I believe our work will make a real difference.
The EU's new clinical trials regulation still has a few implementation challenges to overcome, says Prof. Christian Dittrich.
Research breakthroughs happen more easily when knowledge, data and resources are shared, explains Pierre Meulien.
A Europe whose political and regulatory framework stimulates the growth of innovation in the animal health sector is a Europe that secures a more sustainable future for all, writes Roxane Feller...